Clinical TopicsHome Page Recent ArticlesNewsPatient SafetyPediatricsWorkplace Management

Potential new treatment for peanut allergies

By: Lydia L. Kim, Digital Content Editor

Aimmune Therapeutics is set to present new data on its AR101 compound, Palforzia, a potential new treatment for peanut allergies, in early November 2019 at the American College of Asthma, Allergy, and Immunology (ACAAI) annual meeting.

Palforzia is an emerging oral immunotherapy that’s designed to “reduce the frequency and severity of allergic reactions to accidental peanut exposure,” and is currently being reviewed by the U.S. Food and Drug Administration.

The chief medical officer of Aimmune, Daniel Adelman, MD, has said the following regarding the upcoming presentation: “We’re pleased to be presenting a robust and diverse set of studies related to peanut allergy, ranging from its diagnosis, associated costs and effects on quality of life, to patient selection and integration of potential treatments in clinical practice…The progress we and others have made on behalf of patients and families affected by living with peanut allergies in just the past 12 months has been inspiring and we look forward to learning about additional important advances at this year’s ACAAI meeting.”

The presentation at ACAAI 2019 will cover data from Aimmune’s ARTEMIS and PALISADE studies.

If Palforzia is approved, it could provide a new option for patients with this life-threatening allergy.

Please read Aimmune’s press release here, and learn more about Palforzia here.


The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Test Your Knowledge

Which of the following statements about traumatic hyphema is true?

More Perspectives